ArticleFrontiers in medicine2024

Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.

Miriam M Moser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.